Skip to Content

Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder

TOKYO, Jan 25, 2007 (JCN) - Nippon Shinyaku and Apogepha Arzneimittel GmbH announced on January 16 their decision to terminate an agreement for the development and marketing of NS-8, a novel compound for the treatment of overactive bladder. The decision follows the results of a Proof-of-Concept study undertaken by Apogepha in Europe.

NS-8 is a novel agent discovered by Nippon Shinyaku and was licensed out to Apogepha in October 2003. Apogepha has been conducting clinical studies in Europe, but will discontinue the development of NS-8 due to the lack of sufficient efficacy at the expected therapeutic dosage in the POC study.

The development of NS-8 in Japan has been conducted by Nippon Shinyaku and the Phase I clinical studies were completed. Nippon Shinyaku has discussed internally the future strategy of NS-8 development and has decided to discontinue the NS-8 development as an agent for overactive bladder at home and abroad.

Posted: January 2007